- In January 2025, Thermo Fisher Scientific, announced the launch of its Celiac Disease Testing Kits in the European Union, following the receipt of CE marking. The kits are designed to provide quick and accurate serological testing for individuals suspected of having celiac disease, utilizing advanced technology to improve diagnostic accuracy. These tests are optimized for high throughput and deliver results that assist clinicians in making timely treatment decisions, thus addressing the increasing demand for effective celiac disease diagnostics
- In October 2024, at the American Association of Clinical Chemistry (AACC) Annual Meeting, Abbott Laboratories showcased its advancements in molecular diagnostics, introducing a new Celiac Disease Genetic Test designed to identify genetic markers associated with an increased risk of celiac disease. This new test is aimed at improving early detection and preventive strategies, especially in at-risk populations, with a focus on non-invasive methods that enhance diagnostic efficiency
- In September 2024, at the 42nd European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Congress, Bio-Rad Laboratories presented new data supporting the integration of rapid serology tests for the diagnosis of celiac disease, demonstrating their effectiveness in providing accurate results within minutes. The company highlighted its portfolio of diagnostic tools for celiac disease, emphasizing the importance of early screening and monitoring in pediatric and adult populations
- In September 2024, Medtronic announced the upcoming launch of Celiac Disease Monitoring Systems, which provide continuous monitoring of antibody levels in patients with known celiac disease. This system, expected to be available in Q1 2025, is designed to aid in ongoing disease management by tracking patient response to dietary interventions and ensuring better compliance with gluten-free diets. It features advanced analytics and a user-friendly interface for healthcare providers and patients alike
